




Linton

The Biofabrication Foundry

Lifesciences lacks the manufacturing layer for biofabricated products


Drug discovery, implants, and tissue therapeutics are all moving toward human-relevant, engineered biology, but there doesn't exist a place to manufacture these products repeatably at scale.



1

Drug discovery is still too non-human


2D assays and animal models miss flow, barriers, immune trafficking, matrix remodeling, and systemic human biology.



2

Implants are still too generic

Many medical implants are synthetic, static, and poorly matched to the biological environment they need to integrate with.



3

Tissue therapeutics are still hard to produce


Cells alone are not enough. Living therapies need architecture, vascularization, retrievability, dosing, and scalable manufacturing.

Why Now?

How do we know? Because we have this problem.

Linton is the manufacturing layer for biofabricated products

A bioprinting foundry that turns tissue engineering into repeatable products from human-relevant NAMs, to personalized implants, to living tissue therapeutics.



SOLUTION

Not another research printer | a foundry that bioprints biology into products.

Platform Expansion Roadmap

Each phase funds the next, building infrastructure to propel the next set of products



Phase 1

Linton Printers



Phase 2

Linton NAMs



Phase 3

Linton Medtech



Phase 4

Linton Therapeutics





PHASE 01 · Printers

A proven bioprinting platform

20+ years of innovation, broad applications, and an intact commercial base now sit inside an owner whose strategy has moved elsewhere.

THE PLATFORM

Proven over two decades

- More than 20 years of 3D-bioprinting innovation and peer-reviewed use in the field.
- Published applications span bone regeneration, drug release, soft tissue, cartilage, cell printing, organ printing, and 4D printing.
- Key milestones include successive printer generations, bioprinting cell suspensions, drug-releasing applications, hyperplastic bone work, and new printhead platforms.

3D-BIOPLOTTER CUSTOMERS SPOTLIGHT



THE BASE

What exists today

The product family and installed workflows are still tangible assets, with equipment, software, documentation, and customer familiarity already in market.

3D-BIOPLOTTER SERIES



Manufacturer	Developer	Starter
for advanced and commercial workflows	for tissue-engineering R&D	for accessible entry use

Last year almost \$1M in revenue, with almost half coming from recurring revenue.

THE WINDOW

Why now



- BioPlotter sits inside Desktop Health / ExOne, a German-based owner whose strategic focus has moved elsewhere.
- That creates a rare acquisition window: a proven asset with its core platform and installed base still intact.
- Linton is built to run it stabilize support, re-engage customers, and extend the platform into NAMs and medtech.

A proven, platform with strategic value.



PHASE 02 • NAMs

Biofabricated New Approach Methodologies

Human-relevant biology, Replacing Animal Models for Drug Discovery.

O1 NEED

2D assays and animal-heavy workflows miss systemic human biology.

For many diseases, the critical biology depends on flow, barriers, immune trafficking, matrix remodeling, and tissue drainage.

\$10 Billion Market growing at 13% CAGR

O2 SOLUTION

bfNAM Designer turns tissue, topology, and flow into fabrication-ready systems. Sell services between \$10k-\$100k per experiment.


Scientists configure modular chip layouts, tune geometry, biomaterials, layers, and perfusion before fabrication.

O3 POSITIONING

Linton sits after high-throughput screening and before costly downstream work.

NAMs help teams generate more human-relevant evidence when selecting candidates, refining protocols, and deciding which programs deserve deeper investment.

bfNAMs



Where it fits in the stack



Why now

FDA and NIH focus on NAMs is pushing the market toward more human-relevant evidence.

bfNAM platform that makes biology more human-like exactly where better data can change development decisions.



PHASE 03 · MEDTECH

One platform, a growing *product pipeline*.

Linton Medtech uses the Bioplotter foundry to advance focused programs
Prioritizing vascular grafts as the lead program, with craniofacial and eardrums as potential follow-ons.

SHARED PLATFORM — BIOPLOTTER FOUNDRY

MATAS · PROGRAM

Small-diameter vascular grafts



Today's <6 mm ePTFE / Dacron grafts fail on patency due to thrombosis - a clear biofabricated opening. Received NSF SBIR to continue developing.

Hemodialysis and vascular-access need

JACKSON · PROGRAM

Craniofacial implants




Patient-matched bone constructs - building on the world's first 3D-bioprinted bone implant.

Patient-specific reconstructive pathway

BLAKE · PROGRAM

Bioprinted eardrums



Restoring hearing with printed tympanic membranes - from the team behind the first bioprinted eardrum.

30M chronic eardrum perforations / year

Different product directions, one manufacturing foundry.



PHASE 04 • THERAPEUTICS

Therapeutic Applications

A biofabricated endocrine implant can become the first living product proof point.

Beachhead: chronic hypoparathyroidism

Small tissue mass. Clear missing hormone. Direct feedback signal. Measurable biomarkers. Rare-disease commercial logic.

~70–90K U.S. patients · rare endocrine pricing precedent: ~\$120K–\$285K/year · expected IND → BLA / CBER path




The product is not the cell alone, it is the cell plus architecture: a small, doseable, retrievable microtissue that senses calcium and releases PTH dynamically.

Tissue therapeutic implants that provide a life time of therapy

Rare endocrine tissue platform

parathyroid → adrenal → thyroid → metabolic tissues




A compounding platform advantage.

Every turn of the base business funds the next layer: printers create customers, customers create applications, applications create NAMs and IP, IP becomes medtech, and medtech capabilities open tissue-therapeutic implant opportunities.

- **01 Printer base**
cash + installed users
- **02 NAMs & IP**
insight → designs
- **03 Medtech products**
validated product pathways
- **04 Tissue therapeutics**
implantable tissue upside

The base funds the upside →

Each new layer raises the value of the platform beneath it.





Ricky Solorzano
ENTREPRENEUR · ENGINEER · CEO

Founder has *built the category before*.

Linton is a bioprinting foundry: printers create customers, customers reveal applications, and applications become NAMs, medtech products, and tissue therapeutics.

THE FOUNDRY CASE

Why the foundry is bankable

- Founder-market fit across bioprinting hardware, biology, customers, and commercialization.
- Built Allevi from zero into the world's first desktop bioprinter company, then sold it to 3D Systems.
- Knows how to turn instruments, service, software, and customer workflows into a scalable product platform.
- Can translate customer demand into NAMs, IP, medtech programs, and therapeutic applications.
- Capital-efficient model: base revenue funds infrastructure, credibility, and higher-value products.

THE OPERATOR

The operator built for this foundry

Ricky has lived every layer of the stack: product, hardware, biomaterials, customers, and commercial execution. He is not just buying a printer asset, he is building the manufacturing and application engine for biofabricated products.

\$12M

Capital Managed

3D Systems

ACQUIRER OF ALLEVI

Behind Ricky is a team of bioprinting pioneers spanning science, NAMs, medtech, and therapeutics, credibility to run the base business and build what comes next.

Founder-led execution for a compounding bioprinting foundry.

The technical leader who can *figure out the hard parts*.

Julio brings the rare cross-disciplinary stack BioPlotter needs: bioprinting, microphysiological systems, biomaterials, tissue engineering, and the practical engineering instinct to make complex systems work.

THE BREADTH

Deep across the biofabrication stack

- Recognized by MIT Technology Review Innovators Under 35 for organ-replicating chips and “humanizing” pharmaceutical trials.
- Research footprint spans tissue engineering, microphysiological systems, bioprinting, biomaterials, and tissue microenvironment.
- Worked across microfluidics, hydrogels, multi-organ systems, sensors, and tissue-model platforms, not just one narrow technique.
- Publication record shows broad technical depth: dozens of works and thousands of citations across engineered tissues and in vitro systems.

THE TECHNICAL OPERATOR

The person who makes the system work

Biofabrication fails when biology, hardware, materials, and workflow do not line up. Julio’s value is that he can move between those layers and diagnose what needs to change.

6.8K+
RESEARCH CITATIONS

45+
PUBLICATIONS

Breadth across the field. Practical instinct at the bench. Technical leadership for the platform.



Julio Aleman

FULL TIME - CTO - PH.D. - BIOFABRICATION

The Bioprinting Pioneers

Clinical-grade biofabrication with living-system intelligence



Ricky Solorzano
CEO

Bioprinting Entrepreneur,
Pioneered world's first
desktop bioprinter



Julio Aleman
CTO

Biofabrication Expert,
MIT Review 35 under 35



Y. Shrike Zhang
Scientific Advisor

Professor at Harvard
Medical School




Adam Jakus
Advisor

Pioneered world's first 3D
bioprinted bone implant



Fuel, Build, Scale.

The base business funds the next layer: first restore the Bioplotter, then expand into applications, NAMs, medtech, and tissue therapeutics.



Numbers-first snapshot

Revenue by business unit, profitability, and capital needs at the key buildout milestones.

Metric	Y1	Y3	Y5	Y7	Y9	Y11	Y13	Y15
REVENUE BY BUSINESS UNIT								
BioPlotter revenue	\$1.2	\$3.6	\$4.5	\$4.5	\$4.5	\$4.5	\$4.5	\$4.5
NAMs revenue	\$0.3	\$1.0	\$5.0	\$5.0	\$5.0	\$5.0	\$5.0	\$5.0
Implants revenue	\$0.0	\$0.0	\$0.5	\$6.0	\$25.0	\$65.0	\$105.0	\$135.0
Therapeutics revenue	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$100.0
TOTAL REVENUE	\$1.4	\$4.6	\$10.0	\$15.5	\$34.5	\$74.5	\$114.5	\$244.5
PROFITABILITY, SPEND AND CAPITAL								
Total EBITDA	(\$0.3)	(\$1.5)	(\$0.6)	\$1.4	\$7.5	\$16.5	\$24.5	\$110.5
Spend total (OPEX + R&D)	\$0.7	\$2.9	\$5.0	\$6.3	\$11.6	\$26.6	\$42.6	\$59.6
FCF / burn pre-financing	(\$0.7)	(\$2.4)	(\$2.9)	(\$4.2)	(\$4.0)	\$0.2	\$6.1	\$70.0
New capital needed / raise	\$2.5	\$12.0	\$25.0	\$40.0	—	—	—	—

01 Printers

Segment reaches ~\$4.5M by Y5.

02 NAMs services

5M year by Y5; ~40% margin target.


PRE-SEED RUNWAY

18–24 mo

\$2.5M funds acquisition close + relaunch

BUSINESS DYNAMIC

Base case reaches ~\$9.5M revenue by Y5; EBITDA turns positive as medtech upside enters Y7, Cash can be throttled by managing implants burn



Max Round: \$2.5M

Instrument: YC post-money SAFE

Min Target: \$1.5M

Use of funds: 18–24 months

43% — Team & G&A: Funds lean execution team and company operations.

24% — BioPlotter Relaunch: Closes, integrates, and fuels commercialization.

20% — Vascular Program: Advances feasibility, regulatory, and IP work.

13% — NAMs Platform: Funds pilots, validation, and early BD.

Target dilution: 10%

Minimum checks: Angels \$25k–\$250k;
Funds \$250k–\$1M+



Linton

Ricky Solorzano

ricky@linton.life

[linkedin.com/in/rdsolorzano/](https://www.linkedin.com/in/rdsolorzano/)